The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.

Our results confirm that sCR does not predict a different outcome and indicate that more sensitive techniques are able to identify patients with differing prognoses. We suggest that MRD categories should be implemented over sCR for the future classification of MM responses.